Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Aldeyra Therapeutics: Clinical Trials & FDA Approval Profile

Aldeyra Therapeutics (Global / Institutional) sponsors 29 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 1 active protocols (1 recruiting now), 27 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)3.5%
Median Closed Enrollment vs National (145 pts)95 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Aldeyra Therapeutics
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)29
Active Pipeline (Recruiting Now)1 (1)
Completed vs Stopped Early27 / 1 (3.5%)
Median Closed Actual Enrollment95 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Aldeyra Therapeutics
Hospital Research SiteLocationShared Protocols
Mayo Clinic RochesterRochester, MN2
Emory Winship Cancer InstituteAtlanta, GA2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Aldeyra Therapeutics
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05392192A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic CoughPhase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Aldeyra Therapeutics Interactive Dossier, benchmark peers in Ophthalmology and Sensory, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI